Precision BioSciences Inc DTIL.OQ DTIL.O is expected to show a fall in quarterly revenue when it reports results on August 7 for the period ending June 30 2025
The Durham North Carolina-based company is expected to report a 87.4% decrease in revenue to $6.267 million from $49.9 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Precision BioSciences Inc is for a loss of $1.57 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Precision BioSciences Inc is $21.50, about 77.5% above its last closing price of $4.84
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-1.86
-1.72
-2.21
Missed
-28.7
Dec. 31 2025
-1.96
-2.22
Missed
-13.1
Sep. 30 2024
-2.23
-1.92
-2.25
Missed
-17
Jun. 30 2024
-1.68
-1.50
4.67
Beat
410.3
Mar. 31 2024
-2.01
-1.91
-0.35
Beat
81.7
Dec. 31 2023
-3.99
-2.05
-4.06
Missed
-98.3
Sep. 30 2023
-5.03
-4.87
-2.10
Beat
56.9
Jun. 30 2023
-7.52
-7.32
-3.00
Beat
59
This summary was machine generated August 5 at 14:38 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)